Section 1. Identification

**Product identifier**
Infection Detection Panel I, Part Number 8929000

**Part no. (chemical kit)**
8929000

**Part no.**
- FITC Mouse anti-human CD14 8929996
- PE Mouse anti-human CD64 8929997
- PerCP Mouse anti-human CD45 8929998
- APC Mouse anti-human HLA-DR 8929999
- Lysing solution 891B604

*Relevant identified uses of the substance or mixture and uses advised against*

**Material uses**
For research use only. Not for use in diagnostic procedures (RUO).
- FITC Mouse anti-human CD14 0.25 ml
- PE Mouse anti-human CD64 0.25 ml
- PerCP Mouse anti-human CD45 0.25 ml
- APC Mouse anti-human HLA-DR 0.25 ml
- Lysing solution 5 ml

**Supplier/Manufacturer**
Agilent Technologies Australia Pty Ltd
679 Springvale Road
Mulgrave
Victoria 3170, Australia
1800 802 402

**Emergency telephone number (with hours of operation)**
CHEMTREC®: +(61)-290372994

Section 2. Hazard(s) identification

**Classification of the substance or mixture**

**FITC Mouse anti-human CD14**
H412 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3

**PE Mouse anti-human CD64**
H412 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3

**PerCP Mouse anti-human CD45**
H412 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3

**APC Mouse anti-human HLA-DR**
H412 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3

**Lysing solution**

H302 ACUTE TOXICITY (oral) - Category 4
H330 ACUTE TOXICITY (inhalation) - Category 2
H315 SKIN CORROSION/IRRITATION - Category 2
H319 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2A
H317 SKIN SENSITISATION - Category 1
H350 CARCINOGENICITY - Category 1
Section 2. Hazard(s) identification

<table>
<thead>
<tr>
<th>Lysing solution</th>
<th>Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: &gt; 60%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 1 - 10%</td>
</tr>
<tr>
<td></td>
<td>Percentage of the mixture consisting of ingredient(s) of unknown hazards to the aquatic environment: 9.9%</td>
</tr>
</tbody>
</table>

**GHS label elements**

**Hazard pictograms**: Lysing solution

**Signal word**

- FITC Mouse anti-human CD14: No signal word.
- PE Mouse anti-human CD64: No signal word.
- PerCP Mouse anti-human CD45: No signal word.
- APC Mouse anti-human HLA-DR: No signal word.
- Lysing solution: DANGER

**Hazard statements**

- FITC Mouse anti-human CD14: H412 - Harmful to aquatic life with long lasting effects.
- PE Mouse anti-human CD64: H412 - Harmful to aquatic life with long lasting effects.
- PerCP Mouse anti-human CD45: H412 - Harmful to aquatic life with long lasting effects.
- APC Mouse anti-human HLA-DR: H412 - Harmful to aquatic life with long lasting effects.
- Lysing solution: H302 - Harmful if swallowed.
- H315 - Causes skin irritation.
- H317 - May cause an allergic skin reaction.
- H319 - Causes serious eye irritation.
- H330 - Fatal if inhaled.
- H350 - May cause cancer.

**Precautionary statements**

**Prevention**

- FITC Mouse anti-human CD14: P273 - Avoid release to the environment.
- PE Mouse anti-human CD64: P273 - Avoid release to the environment.
- PerCP Mouse anti-human CD45: P273 - Avoid release to the environment.
- APC Mouse anti-human HLA-DR: P273 - Avoid release to the environment.
- Lysing solution: P201 - Obtain special instructions before use.
- P281 - Use personal protective equipment as required.
- P280 - Wear protective gloves. Wear eye or face protection.
- P260 - Do not breathe vapour.

**Response**

- FITC Mouse anti-human CD14: Not applicable.
- PE Mouse anti-human CD64: Not applicable.
- PerCP Mouse anti-human CD45: Not applicable.
- APC Mouse anti-human HLA-DR: Not applicable.
- Lysing solution: P308 + P313 - IF exposed or concerned: Get medical advice or attention.
### Section 2. Hazard(s) identification

**Storage**

<table>
<thead>
<tr>
<th>Substance/mixture</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>Not applicable.</td>
</tr>
</tbody>
</table>

**Disposal**

<table>
<thead>
<tr>
<th>Substance/mixture</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.</td>
</tr>
</tbody>
</table>

**Supplemental label elements**

**Additional warning phrases**

<table>
<thead>
<tr>
<th>Substance/mixture</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>Not applicable.</td>
</tr>
</tbody>
</table>

**Other hazards which do not result in classification**

<table>
<thead>
<tr>
<th>Substance/mixture</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>None known.</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>None known.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>None known.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>None known.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>None known.</td>
</tr>
</tbody>
</table>

### Section 3. Composition and ingredient information

**Substance/mixture**

<table>
<thead>
<tr>
<th>Substance/mixture</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>Mixture</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>Mixture</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>Mixture</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>Mixture</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

**CAS number/other identifiers**
Section 3. Composition and ingredient information

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>% (w/w)</th>
<th>CAS number</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>&lt;1</td>
<td>26628-22-8</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>&lt;1</td>
<td>26628-22-8</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>&lt;1</td>
<td>26628-22-8</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>&lt;1</td>
<td>26628-22-8</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysing solution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,2’-oxybisethanol</td>
<td>≥30 - ≤60</td>
<td>111-46-6</td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td>≤10</td>
<td>50-00-0</td>
</tr>
</tbody>
</table>

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

**Description of necessary first aid measures**

**Eye contact**
- FITC Mouse anti-human CD14: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
- PE Mouse anti-human CD64: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
- PerCP Mouse anti-human CD45: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
- APC Mouse anti-human HLA-DR: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
- Lysing solution: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.

**Inhalation**
- FITC Mouse anti-human CD14: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- PE Mouse anti-human CD64: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if
### Section 4. First aid measures

<table>
<thead>
<tr>
<th>Antigen Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PerCP Mouse anti-human CD45</strong></td>
<td>Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.</td>
</tr>
<tr>
<td><strong>APC Mouse anti-human HLA-DR</strong></td>
<td>Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.</td>
</tr>
<tr>
<td><strong>Lysing solution</strong></td>
<td>Get medical attention immediately. Call a poison center or physician. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.</td>
</tr>
</tbody>
</table>

**Skin contact**
- **FITC Mouse anti-human CD14**
  - Flush contaminated skin with plenty of water.
  - Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse.

- **PE Mouse anti-human CD64**
  - Flush contaminated skin with plenty of water.
  - Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse.

- **PerCP Mouse anti-human CD45**
  - Flush contaminated skin with plenty of water.
  - Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse.

- **APC Mouse anti-human HLA-DR**
  - Flush contaminated skin with plenty of water.
  - Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing
Section 4. First aid measures

Lysing solution
before reuse. Clean shoes thoroughly before reuse. Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion:

**FITC Mouse anti-human CD14**
Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

**PE Mouse anti-human CD64**
Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

**PerCP Mouse anti-human CD45**
Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

**APC Mouse anti-human HLA-DR**
Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Section 4. First aid measures

Lysing solution

- airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- Wash out mouth with water. Remove dentures if any.
- If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

Potential acute health effects

- **Eye contact**: FITC Mouse anti-human CD14 No known significant effects or critical hazards.  
  PE Mouse anti-human CD64 No known significant effects or critical hazards.  
  PerCP Mouse anti-human CD45 No known significant effects or critical hazards.  
  APC Mouse anti-human HLA-DR No known significant effects or critical hazards.  
- **Inhalation**: FITC Mouse anti-human CD14 No known significant effects or critical hazards.  
  PE Mouse anti-human CD64 No known significant effects or critical hazards.  
  PerCP Mouse anti-human CD45 No known significant effects or critical hazards.  
  APC Mouse anti-human HLA-DR No known significant effects or critical hazards.  
  Lysing solution Causes serious eye irritation.  
- **Skin contact**: FITC Mouse anti-human CD14 No known significant effects or critical hazards.  
  PE Mouse anti-human CD64 No known significant effects or critical hazards.  
  PerCP Mouse anti-human CD45 No known significant effects or critical hazards.  
  APC Mouse anti-human HLA-DR No known significant effects or critical hazards.  
  Lysing solution Causes skin irritation. May cause an allergic skin reaction.  
- **Ingestion**: FITC Mouse anti-human CD14 No known significant effects or critical hazards.  
  PE Mouse anti-human CD64 No known significant effects or critical hazards.  
  PerCP Mouse anti-human CD45 No known significant effects or critical hazards.  
  APC Mouse anti-human HLA-DR No known significant effects or critical hazards.  
  Lysing solution Fatal if inhaled.  
- Lysing solution Harmful if swallowed.

Over-exposure signs/symptoms

- **Eye contact**: FITC Mouse anti-human CD14 No specific data.  
  PE Mouse anti-human CD64 No specific data.  
  PerCP Mouse anti-human CD45 No specific data.  
  APC Mouse anti-human HLA-DR No specific data.  
  Lysing solution Adverse symptoms may include the following:
Section 4. First aid measures

Inhalation:
- FITC Mouse anti-human CD14: No specific data.
- PE Mouse anti-human CD64: No specific data.
- PerCP Mouse anti-human CD45: No specific data.
- APC Mouse anti-human HLA-DR: No specific data.
- Lysing solution: No specific data.

Skin contact:
- FITC Mouse anti-human CD14: No specific data.
- PE Mouse anti-human CD64: No specific data.
- PerCP Mouse anti-human CD45: No specific data.
- APC Mouse anti-human HLA-DR: No specific data.
- Lysing solution: Adverse symptoms may include the following: irritation, redness

Ingestion:
- FITC Mouse anti-human CD14: No specific data.
- PE Mouse anti-human CD64: No specific data.
- PerCP Mouse anti-human CD45: No specific data.
- APC Mouse anti-human HLA-DR: No specific data.
- Lysing solution: No specific data.

Indication of immediate medical attention and special treatment needed, if necessary

Notes to physician:
- FITC Mouse anti-human CD14: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- PE Mouse anti-human CD64: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- PerCP Mouse anti-human CD45: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- APC Mouse anti-human HLA-DR: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- Lysing solution: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments:
- FITC Mouse anti-human CD14: No specific treatment.
- PE Mouse anti-human CD64: No specific treatment.
- PerCP Mouse anti-human CD45: No specific treatment.
- APC Mouse anti-human HLA-DR: No specific treatment.
- Lysing solution: No specific treatment.
Section 4. First aid measures

**Protection of first-aiders**

<table>
<thead>
<tr>
<th>FITC Mouse anti-human CD14</th>
<th>No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.</td>
</tr>
</tbody>
</table>

See toxicological information (Section 11)

Section 5. Firefighting measures

**Extinguishing media**

**Suitable extinguishing media**

<table>
<thead>
<tr>
<th>FITC Mouse anti-human CD14</th>
<th>Use an extinguishing agent suitable for the surrounding fire.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
</tr>
</tbody>
</table>

**Unsuitable extinguishing media**

<table>
<thead>
<tr>
<th>FITC Mouse anti-human CD14</th>
<th>None known.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>None known.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>None known.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>None known.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>None known.</td>
</tr>
</tbody>
</table>

**Specific hazards arising from the chemical**

<table>
<thead>
<tr>
<th>FITC Mouse anti-human CD14</th>
<th>In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.</td>
</tr>
</tbody>
</table>

Date of issue/Date of revision : 25/11/2021  Date of previous issue : 10/08/2020  Version : 2
Section 5. Firefighting measures

Special protective actions for fire-fighters

- **CD45**: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- **APC Mouse anti-human HLA-DR**: In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

Special protective equipment for fire-fighters

- **FITC Mouse anti-human CD14**: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.
- **PE Mouse anti-human CD64**: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.
- **PerCP Mouse anti-human CD45**: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.
- **APC Mouse anti-human HLA-DR**: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Hazardous thermal decomposition products

- **FITC Mouse anti-human CD14**: No specific data.
- **PE Mouse anti-human CD64**: No specific data.
- **PerCP Mouse anti-human CD45**: No specific data.
- **APC Mouse anti-human HLA-DR**: Decomposition products may include the following materials:
  - carbon dioxide
  - carbon monoxide
  - nitrogen oxides
  - sulfur oxides
  - metal oxide/oxides
- **Lysing solution**: In a fire or if heated, a pressure increase will occur and the container may burst.

CD45 and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
## Section 5. Firefighting measures

Lysing solution
Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

## Section 6. Accidental release measures

<table>
<thead>
<tr>
<th>Personal precautions, protective equipment and emergency procedures</th>
<th>For non-emergency personnel</th>
<th>For emergency responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spill material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.</td>
<td>If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in &quot;For non-emergency personnel&quot;.</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spill material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.</td>
<td>If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in &quot;For non-emergency personnel&quot;.</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spill material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.</td>
<td>If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in &quot;For non-emergency personnel&quot;.</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spill material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.</td>
<td>If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in &quot;For non-emergency personnel&quot;.</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spill material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.</td>
<td>If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in &quot;For non-emergency personnel&quot;.</td>
</tr>
</tbody>
</table>
### Environmental precautions

**FITC Mouse anti-human CD14**
- Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.
- Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

**PE Mouse anti-human CD64**
- Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.
- Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

**PerCP Mouse anti-human CD45**
- Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.
- Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

**APC Mouse anti-human HLA-DR**
- Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.
- Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

**Lysing solution**
- Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.
- Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

### Methods and material for containment and cleaning up

**Methods for cleaning up**

**FITC Mouse anti-human CD14**
- Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

**PE Mouse anti-human CD64**
- Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

**PerCP Mouse anti-human CD45**
- Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

**APC Mouse anti-human HLA-DR**
- Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Section 6. Accidental release measures

Lysing solution disposal contractor.
Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Section 7. Handling and storage

Precautions for safe handling

Protective measures: FITC Mouse anti-human CD14
Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Avoid release to the environment. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

PE Mouse anti-human CD64
Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Avoid release to the environment. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

PerCP Mouse anti-human CD45
Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Avoid release to the environment. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

APC Mouse anti-human HLA-DR
Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Avoid release to the environment. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

Lysing solution
Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Avoid exposure - obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
## Section 7. Handling and storage

### Advice on general occupational hygiene

<table>
<thead>
<tr>
<th>Material</th>
<th>Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td></td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td></td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td></td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td></td>
</tr>
</tbody>
</table>

### Conditions for safe storage, including any incompatibilities

<table>
<thead>
<tr>
<th>Material</th>
<th>Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td></td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td></td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td></td>
</tr>
</tbody>
</table>

Date of issue/Date of revision: 25/11/2021  
Date of previous issue: 10/08/2020  
Version: 2
Section 7. Handling and storage

APC Mouse anti-human HLA-DR
Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Lysing solution
Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls and personal protection

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>Exposure limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>Safe Work Australia (Australia, 12/2019).</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>PEAK: 0.11 ppm</td>
</tr>
<tr>
<td></td>
<td>PEAK: 0.3 mg/m³</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>Safe Work Australia (Australia, 12/2019).</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>PEAK: 0.11 ppm</td>
</tr>
<tr>
<td></td>
<td>PEAK: 0.3 mg/m³</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>Safe Work Australia (Australia, 12/2019).</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>PEAK: 0.11 ppm</td>
</tr>
<tr>
<td></td>
<td>PEAK: 0.3 mg/m³</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>Safe Work Australia (Australia, 12/2019).</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>PEAK: 0.11 ppm</td>
</tr>
<tr>
<td></td>
<td>PEAK: 0.3 mg/m³</td>
</tr>
<tr>
<td>Lysing solution</td>
<td>Safe Work Australia (Australia, 12/2019).</td>
</tr>
<tr>
<td>2,2'-oxybisethanol</td>
<td>TWA: 23 ppm 8 hours.</td>
</tr>
<tr>
<td></td>
<td>TWA: 100 mg/m³ 8 hours.</td>
</tr>
<tr>
<td></td>
<td>Safe Work Australia (Australia, 12/2019). Skin sensitiser.</td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td></td>
</tr>
</tbody>
</table>
Section 8. Exposure controls and personal protection

| Appropriate engineering controls | If user operations generate dust, fumes, gas, vapour or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. |
| Environmental exposure controls | Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels. |

Individual protection measures

Hygiene measures: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

Skin protection

Hand protection: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties and safety characteristics

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

Physical state: FITC Mouse anti-human CD14 Liquid. PE Mouse anti-human CD64 PerCP Mouse anti-human CD45 APC Mouse anti-human HLA-DR Lysing solution Liquid.
Section 9. Physical and chemical properties and safety characteristics

Colour:
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

Odour:
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

Odour threshold:
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

pH:
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

Melting point/freezing point:
- FITC Mouse anti-human CD14: 0°C (32°F).
- PE Mouse anti-human CD64: 0°C (32°F).
- PerCP Mouse anti-human CD45: 0°C (32°F).
- APC Mouse anti-human HLA-DR: 0°C (32°F).
- Lysing solution: Not available.

Boiling point, initial boiling point, and boiling range:
- FITC Mouse anti-human CD14: 100°C (212°F).
- PE Mouse anti-human CD64: 100°C (212°F).
- PerCP Mouse anti-human CD45: 100°C (212°F).
- APC Mouse anti-human HLA-DR: 100°C (212°F).
- Lysing solution: Not available.

Flash point:

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>Closed cup</th>
<th>Open cup</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>°C</td>
<td>°F</td>
</tr>
<tr>
<td>Lysing solution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td>83</td>
<td>181.4</td>
</tr>
<tr>
<td>Citric acid, trisodium salt, dihydrate</td>
<td>&gt;100</td>
<td>&gt;212</td>
</tr>
</tbody>
</table>
Section 9. Physical and chemical properties and safety characteristics

### Evaporation rate
- **FITC Mouse anti-human CD14**: Not available.
- **PE Mouse anti-human CD64**: Not available.
- **PerCP Mouse anti-human CD45**: Not available.
- **APC Mouse anti-human HLA-DR**: Not available.
- **Lysing solution**: Not available.

### Flammability
- **FITC Mouse anti-human CD14**: Not applicable.
- **PE Mouse anti-human CD64**: Not applicable.
- **PerCP Mouse anti-human CD45**: Not applicable.
- **APC Mouse anti-human HLA-DR**: Not applicable.
- **Lysing solution**: Not applicable.

### Lower and upper explosion limit/flammability limit
- **FITC Mouse anti-human CD14**: Not available.
- **PE Mouse anti-human CD64**: Not available.
- **PerCP Mouse anti-human CD45**: Not available.
- **APC Mouse anti-human HLA-DR**: Not available.
- **Lysing solution**: Not available.

### Vapour pressure

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>Vapour Pressure at 20°C</th>
<th>Vapour Pressure at 50°C</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mm Hg</td>
<td>kPa</td>
</tr>
<tr>
<td><strong>FITC Mouse anti-human CD14</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>23.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>0.0075</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>PE Mouse anti-human CD64</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>23.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>0.0075</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>PerCP Mouse anti-human CD45</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>23.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>0.0075</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>APC Mouse anti-human HLA-DR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>23.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>0.0075</td>
<td>0.001</td>
</tr>
<tr>
<td>Lysing solution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>23.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td>1</td>
<td>0.13</td>
</tr>
</tbody>
</table>
### Section 9. Physical and chemical properties and safety characteristics

**Relative vapour density**
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

**Relative density**
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

**Solubility**
- FITC Mouse anti-human CD14: Easily soluble in the following materials: cold water and hot water.
- PE Mouse anti-human CD64: Easily soluble in the following materials: cold water and hot water.
- PerCP Mouse anti-human CD45: Easily soluble in the following materials: cold water and hot water.
- APC Mouse anti-human HLA-DR: Easily soluble in the following materials: cold water and hot water.
- Lysing solution: Soluble in the following materials: cold water and hot water.

**Partition coefficient: n-octanol/water**
- FITC Mouse anti-human CD14: Not applicable.
- PE Mouse anti-human CD64: Not applicable.
- PerCP Mouse anti-human CD45: Not applicable.
- APC Mouse anti-human HLA-DR: Not applicable.
- Lysing solution: Not applicable.

**Auto-ignition temperature**

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>°C</th>
<th>°F</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>309</td>
<td>588.2</td>
<td>EU A.16</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>309</td>
<td>588.2</td>
<td>EU A.16</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>309</td>
<td>588.2</td>
<td>EU A.16</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>309</td>
<td>588.2</td>
<td>EU A.16</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysing solution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,2'-oxybisethanol</td>
<td>229</td>
<td>444.2</td>
<td>DIN EN 14522-S</td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td>430</td>
<td>806</td>
<td></td>
</tr>
</tbody>
</table>
## Section 9. Physical and chemical properties and safety characteristics

### Decomposition temperature
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

### Viscosity
- FITC Mouse anti-human CD14: Not available.
- PE Mouse anti-human CD64: Not available.
- PerCP Mouse anti-human CD45: Not available.
- APC Mouse anti-human HLA-DR: Not available.
- Lysing solution: Not available.

### Particle characteristics
- **Median particle size**
  - FITC Mouse anti-human CD14: Not applicable.
  - PE Mouse anti-human CD64: Not applicable.
  - PerCP Mouse anti-human CD45: Not applicable.
  - APC Mouse anti-human HLA-DR: Not applicable.
  - Lysing solution: Not applicable.

## Section 10. Stability and reactivity

### Reactivity
- FITC Mouse anti-human CD14: No specific test data related to reactivity available for this product or its ingredients.
- PE Mouse anti-human CD64: No specific test data related to reactivity available for this product or its ingredients.
- PerCP Mouse anti-human CD45: No specific test data related to reactivity available for this product or its ingredients.
- APC Mouse anti-human HLA-DR: No specific test data related to reactivity available for this product or its ingredients.
- Lysing solution: No specific test data related to reactivity available for this product or its ingredients.

### Chemical stability
- FITC Mouse anti-human CD14: The product is stable.
- PE Mouse anti-human CD64: The product is stable.
- PerCP Mouse anti-human CD45: The product is stable.
- APC Mouse anti-human HLA-DR: The product is stable.
- Lysing solution: The product is stable.

### Possibility of hazardous reactions
- FITC Mouse anti-human CD14: Under normal conditions of storage and use, hazardous reactions will not occur.
- PE Mouse anti-human CD64: Under normal conditions of storage and use, hazardous reactions will not occur.
- PerCP Mouse anti-human CD45: Under normal conditions of storage and use, hazardous reactions will not occur.
- APC Mouse anti-human HLA-DR: Under normal conditions of storage and use, hazardous reactions will not occur.
- Lysing solution: Under normal conditions of storage and use, hazardous reactions will not occur.
Section 10. Stability and reactivity

**Conditions to avoid**: FITC Mouse anti-human CD14, PE Mouse anti-human CD64, PerCP Mouse anti-human CD45, APC Mouse anti-human HLA-DR, Lysing solution. No specific data.

**Incompatible materials**: FITC Mouse anti-human CD14, PE Mouse anti-human CD64, PerCP Mouse anti-human CD45, APC Mouse anti-human HLA-DR, Lysing solution. May react or be incompatible with oxidising materials.

**Hazardous decomposition products**: FITC Mouse anti-human CD14, PE Mouse anti-human CD64, PerCP Mouse anti-human CD45, APC Mouse anti-human HLA-DR, Lysing solution. Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

**Information on toxicological effects**

**Acute toxicity**

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Result</th>
<th>Species</th>
<th>Dose</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>LC50 Inhalation Dusts and mists</td>
<td>Rat - Male, Female</td>
<td>0.054 to 0.52 mg/l</td>
<td>4 hours</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>LD50 Dermal</td>
<td>Rabbit</td>
<td>20 mg/kg</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>LD50 Dermal</td>
<td>Rat</td>
<td>50 mg/kg</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>LD50 Oral</td>
<td>Rat</td>
<td>27 mg/kg</td>
<td>-</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>LC50 Inhalation Dusts and mists</td>
<td>Rat - Male, Female</td>
<td>0.054 to 0.52 mg/l</td>
<td>4 hours</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>LD50 Dermal</td>
<td>Rabbit</td>
<td>20 mg/kg</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>LD50 Dermal</td>
<td>Rat</td>
<td>50 mg/kg</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>LD50 Oral</td>
<td>Rat</td>
<td>27 mg/kg</td>
<td>-</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>LC50 Inhalation Dusts and mists</td>
<td>Rat - Male, Female</td>
<td>0.054 to 0.52 mg/l</td>
<td>4 hours</td>
</tr>
<tr>
<td>Sodium azide</td>
<td>LD50 Dermal</td>
<td>Rabbit</td>
<td>20 mg/kg</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>LD50 Dermal</td>
<td>Rat</td>
<td>50 mg/kg</td>
<td>-</td>
</tr>
</tbody>
</table>

**Date of issue/Date of revision**: 25/11/2021
**Date of previous issue**: 10/08/2020
**Version**: 2
Section 11. Toxicological information

### LD50 Oral
- Rat: 27 mg/kg

### LD50 Dermal
- Rabbit: 20 mg/kg
- Rat: 50 mg/kg
- Rabbit: 27 mg/kg

### LD50 Dermal
- Rabbit: 11890 mg/kg
- Rat: 12000 mg/kg

### LD50 Oral
- Rat: 100 mg/kg

### LD50 Oral
- Rat: 12000 mg/kg
- Rabit: 100 mg/kg

### LD50 Dermal
- Rabbit: 270 mg/kg
- Rat: 24 hours 100 mg

### LD50 Dermal
- Rabbit: 270 mg/kg
- Rat: 24 hours 50 mg

### LD50 Dermal
- Rabbit: 270 mg/kg
- Rat: 24 hours 0.8 %

### LD50 Dermal
- Rabbit: 270 mg/kg
- Rat: 24 hours 0.8 %

### LD50 Dermal
- Rabbit: 270 mg/kg
- Rat: 24 hours 0.8 %

### LC50 Inhalation Dusts and mists
- Rat - Male, Female: 0.054 to 0.52 mg/l, 4 hours

### Lysing solution
- 2,2’ -oxybisethanol
  - LD50 Dermal: Rabbit: 11890 mg/kg
  - LD50 Oral: Rat: 12000 mg/kg

### Formaldehyde, solution
- LD50 Dermal
  - Rabbit: 270 mg/kg
  - Rat: 24 hours 50 mg

### Irritation/Corrosion

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Result</th>
<th>Species</th>
<th>Score</th>
<th>Exposure</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysing solution</td>
<td>Eyes - Mild irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>50 mg</td>
<td>-</td>
</tr>
<tr>
<td>2,2’ -oxybisethanol</td>
<td>Skin - Mild irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>500 mg</td>
<td>-</td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td>Eyes - Severe irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>24 hours 750 ug</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Skin - Moderate irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>750 ug</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Skin - Severe irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>24 hours 50 mg</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Skin - Severe irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>24 hours 2 mg</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Skin - Severe irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>0.8 %</td>
<td>-</td>
</tr>
</tbody>
</table>

### Sensitisation
Not available.

### Mutagenicity
- Conclusion/Summary: Not available.

### Carcinogenicity
- Conclusion/Summary: Not available.

### Reproductive toxicity
- Conclusion/Summary: Not available.

### Teratogenicity
- Conclusion/Summary: Not available.

### Specific target organ toxicity (single exposure)
Not available.

### Specific target organ toxicity (repeated exposure)
Not available.

### Aspiration hazard
Not available.

### Information on likely routes of exposure
- FITC Mouse anti-human CD14
- PE Mouse anti-human CD64
- PerCP Mouse anti-human CD45
- APC Mouse anti-human HLA-DR
- Lysing solution

Routes of entry anticipated: Oral, Dermal, Inhalation.

### Potential acute health effects

Date of issue/Date of revision: 25/11/2021  
Date of previous issue: 10/08/2020  
Version: 2  
22/28
Section 11. Toxicological information

Eye contact:
- FITC Mouse anti-human CD14: No known significant effects or critical hazards.
- PE Mouse anti-human CD64: No known significant effects or critical hazards.
- PerCP Mouse anti-human CD45: No known significant effects or critical hazards.
- APC Mouse anti-human HLA-DR: No known significant effects or critical hazards.
- Lysing solution: Causes serious eye irritation.

Inhalation:
- FITC Mouse anti-human CD14: No known significant effects or critical hazards.
- PE Mouse anti-human CD64: No known significant effects or critical hazards.
- PerCP Mouse anti-human CD45: No known significant effects or critical hazards.
- APC Mouse anti-human HLA-DR: No known significant effects or critical hazards.
- Lysing solution: Fatal if inhaled.

Skin contact:
- FITC Mouse anti-human CD14: No known significant effects or critical hazards.
- PE Mouse anti-human CD64: No known significant effects or critical hazards.
- PerCP Mouse anti-human CD45: No known significant effects or critical hazards.
- APC Mouse anti-human HLA-DR: No known significant effects or critical hazards.
- Lysing solution: Causes skin irritation. May cause an allergic skin reaction.

Ingestion:
- FITC Mouse anti-human CD14: No known significant effects or critical hazards.
- PE Mouse anti-human CD64: No known significant effects or critical hazards.
- PerCP Mouse anti-human CD45: No known significant effects or critical hazards.
- APC Mouse anti-human HLA-DR: No known significant effects or critical hazards.
- Lysing solution: Harmful if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics:

Eye contact:
- FITC Mouse anti-human CD14: No specific data.
- PE Mouse anti-human CD64: No specific data.
- PerCP Mouse anti-human CD45: No specific data.
- APC Mouse anti-human HLA-DR: No specific data.
- Lysing solution: Adverse symptoms may include the following: pain or irritation, watering, redness.

Inhalation:
- FITC Mouse anti-human CD14: No specific data.
- PE Mouse anti-human CD64: No specific data.
- PerCP Mouse anti-human CD45: No specific data.
- APC Mouse anti-human HLA-DR: No specific data.
- Lysing solution: No specific data.

Skin contact:
- FITC Mouse anti-human CD14: No specific data.
- PE Mouse anti-human CD64: No specific data.
- PerCP Mouse anti-human CD45: No specific data.
- APC Mouse anti-human HLA-DR: No specific data.

Date of issue/Date of revision: 25/11/2021
Date of previous issue: 10/08/2020
Version: 2
# Section 11. Toxicological information

<table>
<thead>
<tr>
<th>Ingestion</th>
<th>FITC Mouse anti-human CD14</th>
<th>No specific data.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>No specific data.</td>
<td></td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>No specific data.</td>
<td></td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>No specific data.</td>
<td></td>
</tr>
<tr>
<td>Lysing solution</td>
<td>No specific data.</td>
<td></td>
</tr>
</tbody>
</table>

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

#### Short term exposure
- **Potential immediate effects**: Not available.
- **Potential delayed effects**: Not available.

#### Long term exposure
- **Potential immediate effects**: Not available.
- **Potential delayed effects**: Not available.
- **Potential chronic health effects**:
  - **General**
    - **FITC Mouse anti-human CD14**: No known significant effects or critical hazards.
    - **PE Mouse anti-human CD64**: No known significant effects or critical hazards.
    - **PerCP Mouse anti-human CD45**: No known significant effects or critical hazards.
    - **APC Mouse anti-human HLA-DR**: No known significant effects or critical hazards.
    - **Lysing solution**: Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
  - **Carcinogenicity**
    - **FITC Mouse anti-human CD14**: No known significant effects or critical hazards.
    - **PE Mouse anti-human CD64**: No known significant effects or critical hazards.
    - **PerCP Mouse anti-human CD45**: No known significant effects or critical hazards.
    - **APC Mouse anti-human HLA-DR**: No known significant effects or critical hazards.
    - **Lysing solution**: May cause cancer. Risk of cancer depends on duration and level of exposure.
  - **Mutagenicity**
    - **FITC Mouse anti-human CD14**: No known significant effects or critical hazards.
    - **PE Mouse anti-human CD64**: No known significant effects or critical hazards.
    - **PerCP Mouse anti-human CD45**: No known significant effects or critical hazards.
    - **APC Mouse anti-human HLA-DR**: No known significant effects or critical hazards.
    - **Lysing solution**: No known significant effects or critical hazards.
  - **Reproductive toxicity**
    - **FITC Mouse anti-human CD14**: No known significant effects or critical hazards.
    - **PE Mouse anti-human CD64**: No known significant effects or critical hazards.
    - **PerCP Mouse anti-human CD45**: No known significant effects or critical hazards.
    - **APC Mouse anti-human HLA-DR**: No known significant effects or critical hazards.
    - **Lysing solution**: No known significant effects or critical hazards.

### Numerical measures of toxicity

**Date of issue/Date of revision**: 25/11/2021  
**Date of previous issue**: 10/08/2020  
**Version**: 2
**Section 11. Toxicological information**

### Acute toxicity estimates

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Oral (mg/kg)</th>
<th>Dermal (mg/kg)</th>
<th>Inhalation (gases) (ppm)</th>
<th>Inhalation (vapours) (mg/l)</th>
<th>Inhalation (dusts and mists) (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>27</td>
<td>20</td>
<td>N/A</td>
<td>N/A</td>
<td>0.054</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>27</td>
<td>20</td>
<td>N/A</td>
<td>N/A</td>
<td>0.054</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>27</td>
<td>20</td>
<td>N/A</td>
<td>N/A</td>
<td>0.054</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>27</td>
<td>20</td>
<td>N/A</td>
<td>N/A</td>
<td>0.054</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysing solution</td>
<td>628.9</td>
<td>2727.3</td>
<td>N/A</td>
<td>1.8</td>
<td>N/A</td>
</tr>
<tr>
<td>Lysing solution</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,2'-oxybisethanol</td>
<td>500</td>
<td>11890</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td>100</td>
<td>270</td>
<td>N/A</td>
<td>0.5</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Section 12. Ecological information**

### Toxicity

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Result</th>
<th>Species</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>Acute EC50 9200 μg/l Marine water&lt;br&gt;Acute EC50 6.4 mg/l Fresh water&lt;br&gt;Acute EC50 4.2 mg/l Fresh water&lt;br&gt;Acute LC50 0.68 mg/l Fresh water&lt;br&gt;Chronic NOEC 5600 μg/l Marine water</td>
<td>Algae - Macroystis pyrifera&lt;br&gt;Crustaceans - Simocephalus serrulatus - Larvae&lt;br&gt;Daphnia - Daphnia pulex - Larvae&lt;br&gt;Fish - Lepomis macrochirus&lt;br&gt;Algae - Macroystis pyrifera</td>
<td>96 hours&lt;br&gt;48 hours&lt;br&gt;48 hours&lt;br&gt;96 hours&lt;br&gt;96 hours</td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>Acute EC50 9200 μg/l Marine water&lt;br&gt;Acute EC50 6.4 mg/l Fresh water&lt;br&gt;Acute EC50 4.2 mg/l Fresh water&lt;br&gt;Acute LC50 0.68 mg/l Fresh water&lt;br&gt;Chronic NOEC 5600 μg/l Marine water</td>
<td>Algae - Macroystis pyrifera&lt;br&gt;Crustaceans - Simocephalus serrulatus - Larvae&lt;br&gt;Daphnia - Daphnia pulex - Larvae&lt;br&gt;Fish - Lepomis macrochirus&lt;br&gt;Algae - Macroystis pyrifera</td>
<td>96 hours&lt;br&gt;48 hours&lt;br&gt;48 hours&lt;br&gt;96 hours&lt;br&gt;96 hours</td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>Acute EC50 9200 μg/l Marine water&lt;br&gt;Acute EC50 6.4 mg/l Fresh water&lt;br&gt;Acute EC50 4.2 mg/l Fresh water&lt;br&gt;Acute LC50 0.68 mg/l Fresh water&lt;br&gt;Chronic NOEC 5600 μg/l Marine water</td>
<td>Algae - Macroystis pyrifera&lt;br&gt;Crustaceans - Simocephalus serrulatus - Larvae&lt;br&gt;Daphnia - Daphnia pulex - Larvae&lt;br&gt;Fish - Lepomis macrochirus&lt;br&gt;Algae - Macroystis pyrifera</td>
<td>96 hours&lt;br&gt;48 hours&lt;br&gt;48 hours&lt;br&gt;96 hours&lt;br&gt;96 hours</td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>Acute EC50 9200 μg/l Marine water&lt;br&gt;Acute EC50 6.4 mg/l Fresh water&lt;br&gt;Acute EC50 4.2 mg/l Fresh water&lt;br&gt;Acute LC50 0.68 mg/l Fresh water&lt;br&gt;Chronic NOEC 5600 μg/l Marine water</td>
<td>Algae - Macroystis pyrifera&lt;br&gt;Crustaceans - Simocephalus serrulatus - Larvae&lt;br&gt;Daphnia - Daphnia pulex - Larvae&lt;br&gt;Fish - Lepomis macrochirus&lt;br&gt;Algae - Macroystis pyrifera</td>
<td>96 hours&lt;br&gt;48 hours&lt;br&gt;48 hours&lt;br&gt;96 hours&lt;br&gt;96 hours</td>
</tr>
</tbody>
</table>
Section 12. Ecological information

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Test</th>
<th>Result</th>
<th>Dose</th>
<th>Inoculum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysing solution</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,2' -oxybisethanol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formaldehyde, solution</td>
<td>OECD 301A Ready Biodegradability - DOC Die-Away Test</td>
<td>99 % - Readily - 28 days</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sodium azide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute EC50 9200 μg/l Marine water</td>
<td>Algae - Macrocyopsis pyrifera</td>
<td>96 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute EC50 6.4 mg/l Fresh water</td>
<td>Crustaceans - Simocephalus serrulatus - Larvae</td>
<td>48 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute EC50 4.2 mg/l Fresh water</td>
<td>Daphnia - Daphnia pulex - Larvae</td>
<td>48 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute LC50 0.68 mg/l Fresh water</td>
<td>Fish - Lepomis macrochirus</td>
<td>96 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic NOEC 5600 μg/l Marine water</td>
<td>Algae - Macrocyopsis pyrifera</td>
<td>96 hours</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bioaccumulative potential

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>LogP&lt;sub&gt;oct&lt;/sub&gt;</th>
<th>BCF</th>
<th>Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysing solution</td>
<td>-1.98, 0.35</td>
<td>100</td>
<td>low</td>
</tr>
</tbody>
</table>

Mobility in soil

Soil/water partition coefficient (K<sub>oc</sub>) : Not available.

Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or
Section 13. Disposal considerations

Landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

ADG / IMDG / IATA: Not regulated as Dangerous Goods according to the ADG Code.

Special precautions for user: Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments: Not available.

Section 15. Regulatory information

Standard for the Uniform Scheduling of Medicines and Poisons

6

Model Work Health and Safety Regulations - Scheduled Substances

No listed substance

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia: Not determined.
Canada: Not determined.
China: All components are listed or exempted.
Europe: Not determined.
Japan:
  Japan inventory (CSCL): Not determined.
  Japan inventory (ISHL): Not determined.
New Zealand: Not determined.
Philippines: Not determined.
Republic of Korea: Not determined.
Taiwan: All components are listed or exempted.
Thailand: Not determined.
Turkey: Not determined.
United States: All components are active or exempted.
Viet Nam: Not determined.

Date of issue/Date of revision: 25/11/2021
Date of previous issue: 10/08/2020
Version: 2
Section 16. Any other relevant information

History

| Date of issue/Date of revision | 25/11/2021 |
| Date of previous issue        | 10/08/2020 |
| Version                       | 2          |

Key to abbreviations

- ADG = Australian Dangerous Goods
- ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road
- ATE = Acute Toxicity Estimate
- BCF = Bioconcentration Factor
- GHS = Globally Harmonized System of Classification and Labelling of Chemicals
- IATA = International Air Transport Association
- IBC = Intermediate Bulk Container
- IMDG = International Maritime Dangerous Goods
- LogPow = logarithm of the octanol/water partition coefficient
- N/A = Not available
- SUSMP = Standard Uniform Schedule of Medicine and Poisons
- UN = United Nations

Procedure used to derive the classification

<table>
<thead>
<tr>
<th>Classification</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC Mouse anti-human CD14</td>
<td>Calculation method</td>
</tr>
<tr>
<td>LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3</td>
<td></td>
</tr>
<tr>
<td>PE Mouse anti-human CD64</td>
<td>Calculation method</td>
</tr>
<tr>
<td>LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3</td>
<td></td>
</tr>
<tr>
<td>PerCP Mouse anti-human CD45</td>
<td>Calculation method</td>
</tr>
<tr>
<td>LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3</td>
<td></td>
</tr>
<tr>
<td>APC Mouse anti-human HLA-DR</td>
<td>Calculation method</td>
</tr>
<tr>
<td>LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3</td>
<td></td>
</tr>
<tr>
<td>Lysing solution</td>
<td>Calculation method</td>
</tr>
<tr>
<td>ACUTE TOXICITY (oral) - Category 4</td>
<td>Calculation method</td>
</tr>
<tr>
<td>ACUTE TOXICITY (inhalation) - Category 2</td>
<td></td>
</tr>
<tr>
<td>SKIN CORROSION/IRRITATION - Category 2</td>
<td></td>
</tr>
<tr>
<td>SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2A</td>
<td></td>
</tr>
<tr>
<td>SKIN SENSITISATION - Category 1</td>
<td>Calculation method</td>
</tr>
<tr>
<td>CARCINOGENICITY - Category 1</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>

References

- Not available.

Indicates information that has changed from previously issued version.

Notice to reader

Disclaimer: The information contained in this document is based on Agilent’s state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.